



Australian
Prostate Cancer
BioResource


Australian Prostate Cancer BioResource

Pamela Saunders on behalf of the BioResource Management Committee and the State Node Coordinators of the Australian Prostate Cancer BioResource



SIGNIFICANCE

The Australian Prostate Cancer BioResource (APCB) is a national federated biobank that provides a unique quality assured facility for the collection, storage and access to biospecimens and associated data to support prostate cancer research. The APCB is funded by the Prostate Cancer Foundation of Australia (PCFA).



SERVICES


The APCB was established as a prospective collection of biospecimens from men treated surgically for localised prostate cancer. More recently diversification of the collection at each state node has enable the APCB to offer unique services, such as tailored boutique collections of aggressive disease, incorporation of data into clinical registries, partnering with body bequest donor programs to bank metastatic material, and banking material from clinical trials.

Table 1: Total number of resources in APCB BioResource (March 2015)

Resources	Numbers
Fresh tissue (cancer/benign cores) from radical prostatectomies and TURP tissue	>11,300
Paraffin embedded prostate tissue	5,030
Bloods (buffy coat cells/serum/plasma)	126,560
Tissue Microarrays	
	Pilot array (10 biospecimens [cancer/benign])
	Gleason array (150 biospecimens)
	Normal tissue array (160 biospecimens)
	Cell line array (12 biospecimens)

RESULTS

To date (Oct 2007-March 2015) the APCB has collected 143,320 biospecimens from 5,630 men with prostate cancer and has distributed 8,136 biospecimens to 48 different research groups on 90 occasions.



- PARAFFIN (24%)
- BUFFY (49%)
- CELL LINE ARRAY (<1%)
- DNA (<1%)
- FRESH TISSUE (10%)
- PLASMA (<1%)
- NORMAL TISSUE ARRAY (2%)
- RNA (2%)
- SERUM (5%)
- PILOT ARRAY (2%)
- GLEASON ARRAY (6%)

Figure 1: Biospecimen distribution for the APCB (% March 2015)

The APCB has provided resources to build and contribute to Australasian cohorts in large scale genetic, genomic and proteomic biomarker studies, including the following research programs:

- PRACTICAL Genome Wide Association Study
- Irish Biomarker Consortium
- Movember Global Action Plan (GAP) Initiative

Our alliance with ANZUP Clinical Trials has enabled the APCB to provide expertise and infrastructure to bank biospecimens from the TROG sponsored Radiotherapy-adjuvant versus early salvage (RAVES) trial.

CONCLUSION

The APCB is a national BioResource with a collection of high quality specimens and relevant clinical and pathological data from prostate cancer patients. This collection will continue to become an important resource for prostate cancer research both nationally and internationally.

Questions...? Visit our website www.apcbioresource.org.au

BRISBANE, QLD

Judith Clements, Chair, Executive Committee
Trina Yeadon, National Project Manager
Allison Eckert, Coordinator
Queensland University of Technology

SYDNEY, NSW

Lisa Horvath, Executive Committee
Anne-Maree Haynes and Sarita Tiwari, Coordinators
Garvan Institute of Medical Research and
The Kinghorn Cancer Centre

MELBOURNE, VIC

Gail Risbridger, Executive Committee
Renea Taylor, Executive Committee
Melissa Papargiris, Coordinator
Monash University

ADELAIDE, SA

Wayne Tilley, Executive Committee
Lisa Butler, Executive Committee
Pam Saunders, Coordinator
Hanson Institute